Education
About Us
Working with TipRanks
Follow Us
Adial Pharmaceuticals Inc (ADIL)
NASDAQ:ADIL
Total Valuation
Adial Pharmaceuticals has a market cap or net worth of $6.40M. The enterprise value is -$2.70M.
Market Cap$6.40M
Enterprise Value-$2.70M
Share Statistics
Adial Pharmaceuticals has 26,649,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,649,588
Owned by Insiders7.44%
Owned by Institutions0.28%
Financial Efficiency
Adial Pharmaceuticals’s return on equity (ROE) is -3.24 and return on invested capital (ROIC) is -203.65%.
Return on Equity (ROE)-3.24
Return on Assets (ROA)-2.62
Return on Invested Capital (ROIC)-203.65%
Return on Capital Employed (ROCE)-2.04
Revenue Per Employee0.00
Profits Per Employee-2.64M
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Adial Pharmaceuticals is ―. Adial Pharmaceuticals’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio4.62
Price to Fair Value4.62
Price to FCF-2.71
Price to Operating Cash Flow-1.03
PEG Ratio0.02
Income Statement
In the last 12 months, Adial Pharmaceuticals had revenue of 0.00 and earned -13.20M in profits. Earnings per share was -0.71.
Revenue0.00
Gross Profit0.00
Operating Income-8.28M
Pretax Income-13.20M
Net Income-13.20M
EBITDA-8.28M
Earnings Per Share (EPS)-0.71
Cash Flow
In the last 12 months, operating cash flow was -6.62M and capital expenditures 3.00, giving a free cash flow of -6.62M billion.
Operating Cash Flow-6.62M
Free Cash Flow-6.62M
Free Cash Flow per Share-0.25
Dividends & Yields
Adial Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-76.19%
50-Day Moving Average0.32
200-Day Moving Average0.46
Relative Strength Index (RSI)30.42
Average Volume (3m)746.19K
Important Dates
Adial Pharmaceuticals upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Adial Pharmaceuticals as a current ratio of 4.16, with Debt / Equity ratio of 0.00%
Current Ratio4.16
Quick Ratio4.16
Debt to Market Cap0.00
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Adial Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Adial Pharmaceuticals EV to EBITDA ratio is -1.14, with an EV/FCF ratio of -2.17.
EV to Sales0.00
EV to EBITDA-1.14
EV to Free Cash Flow-2.17
EV to Operating Cash Flow-2.17
Balance Sheet
Adial Pharmaceuticals has $4.61M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.61M billion.
Cash & Marketable Securities$4.61M
Total Debt$0.00
Net Cash$4.61M
Net Cash Per Share$0.17
Tangible Book Value Per Share$0.22
Margins
Gross margin is -75.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-75.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Adial Pharmaceuticals is $1.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.50
Price Target Upside500.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast78.52%